A hidden nonfunctioning kidney in autosomal dominant polycystic kidney disease. [PDF]
Jung Y, Kim YN, Shin HS, Rim H.
europepmc +1 more source
Paradoxical Hyponatremia on High-Dose Tolvaptan in ADPKD. [PDF]
De Rosa LI +14 more
europepmc +1 more source
HHV-6 Encephalitis Presenting With Severe SIADH and CO₂ Narcosis in Non-Transplant Smoldering Adult T-Cell Leukemia/Lymphoma. [PDF]
Tateishi K +8 more
europepmc +1 more source
Efficacy and safety of tolvaptan in rapidly progressing autosomal dominant polycystic kidney disease: a single-center, prospective, single-arm study. [PDF]
Zhou L, Li W.
europepmc +1 more source
Mid-Term Impact of Kampo Goreisan in Patients with Congestive Heart Failure Receiving Tolvaptan-Incorporated Medical Therapy. [PDF]
Hida Y, Imamura T, Kinugawa K.
europepmc +1 more source
In Reply: Pseudo-Index Events cannot be Configured on the TriNetX Platform. [PDF]
Wu TK.
europepmc +1 more source
Evidence for a tubular basement membrane-cilia connection in autosomal dominant polycystic kidney disease pathogenesis. [PDF]
Sussman CR, Harris PC.
europepmc +1 more source
Effect of tolvaptan on the prognosis of patients with rapidly progressive autosomal dominant polycystic kidney disease: a prospective open-label study. [PDF]
Zhou L, Li W.
europepmc +1 more source
Diffusion MRI Radiomics Predict Renal Function Decline in ADPKD. [PDF]
Bargagli M +9 more
europepmc +1 more source
Treatment of Autosomal Dominant Polycystic Kidney Disease: Integrating Clinical Practice Guidelines, Patient Perspectives, and Real-World Effectiveness. [PDF]
Rangan G.
europepmc +1 more source

